Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 Genitourinary Cancers Symposium /
Crizotinib for advanced papillary renal cell carcinoma with MET mutations or amplification

8th - 10th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.02.18
Views: 885

Prof Patrick Schöffski - The Katholieke Universiteit Leuven, Leuven, Belgium

Prof Schöffski speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about the final results of the CREATE phase II trial, looking at the effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 (PRCC1) with MET mutations or amplification.

He describes the few MET patients had a good objective response rate (ORR) to crizotinib (50%) with good PFS.

The MET- patients responded more sporadically with lower ORR and PFS. 

Therefore crizotinib could be suitable for those PRCC1 patients with MET mutations in tumour tissue.

Also, the sporadic results in patients with MET- mutations suggests other alterations of MET signalling - this could mean there is still a way for these patients to receive benefits from crizotinib.

The results are promising, however PRCC1 is such a rare disease that it will be difficult to achieve a large enough patient cohort for a definitive trial.  

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation